

Product Catalogue

2019-2020

TE  GEN 透景

Tellgen Corporation

TE  **GEN** 透景

Deeper understanding of life

PROFILE

INTRODUCTION

TECHNOLOGY--Tellgenplex™

TECHNOLOGY--Chemiluminescence immunoassay

TECHNOLOGY—Clinical Chemistry

TECHNOLOGY—Molecular tests

SARS-COV-2 Products

HPV GENOTYPING

Y-CHROMOSOME MICRODELETION

SERVICE & SUPPORT

Road of Tellgen

- **2003**

Tellgen was found in Zhangjiang Hi-Tech Park, Pudong and became the first development partner of Luminex Corporation based on xMAP® technology in China.

- **2007**

Tellgenplex™ Tumor Marker Detection Kit won high-tech award of Zhangjiang Hi-Tech Park

- **2009**

Tellgen Tumor Marker Detection Kit and Tellgenplex™ HPV DNA Test Kit got clearance from SFDA

- **2010**

Tellgen developed pharmacogenomic panel of EGFR/K-ras/B-raf on Oncology area based in Tellgenplex™ technology

- **2011**

Tellgen developed EGFR/K-ras/B-raf reagents based on TEEM™ PCR

- **2013**

Tellgen PGI /II Detection Kit got clearance from NMPA

- **2014**

Tellgen HPV 2+12/ 5+9 Detection Kit got clearance from NMPA

- **2015**

Tellgen Y-CHROMOSOME MICRODELETION, Tumor Marker, EGFR, ToRCH, TESMI 3999 got clearance from NMPA

- **2016**

Tellgen NT-proBNP got clearance from NMPA, HPV GENOTYPING, HPV 2+12/5+9, Y-CHROMOSOME, EGFR, K-Ras, B-RAF and SHOX2 and RASSF1A DNA methylation got clearance from CE.

- **2017**

Tellgen has been listed on the Growth Enterprise Market of Shenzhen Stock Exchange(stock code: 300642)

- **2018**

Tellgen introduced a total laboratory automation streamline: TESMI Connection Modules (TCM).

- **2020**

SARS-CoV-2 RTPCR kit and SARS-CoV-2 cartridge PCR kit got clearance from CE.

INTRODUCTION



Tellgen corporation(stock code: 300642) is a public company specializing in the development and manufacture of multiple biomarkers and high throughput platform of in vitro diagnostic products. The company was founded in 2003 and headquartered in Shanghai Zhangjiang Hi-Tech Park.

The Tellgen Corporation focuses on tumor markers detection ,provide total solution from screening to prognosis evaluation related products for customers. The methodology platform employed including immunofluorescence, chemiluminescence immunoassay and multiple fluorescent PCR, mass spectrometry, etc.

Tellgen is one of the global strategic partners with Luminex Corp. Meanwhile, Tellgen is the first one to launch an automated high-throughput immunoassay system (TESMI) based on fluorescence flowcytometry technology. In 2019, we have introduced a total laboratory automation streamline: TЕСMI Connection Modules (TCM).

Tellgen corporation will always adhere to the R & D philosophy of “internalizing technology knowledge globally & ploughing self-innovation locally”, Tellgen Coporation strives to become an influential company in the field of international life science and contribute to public health.

TECHNOLOGY--*Tellgenplex*TM

*Tellgenplex*TM is a technology based on xMAP technology combines advanced fluidics, optics, and digital signal processing with proprietary microsphere technology to deliver multiplexed assay capabilities. color-codes tiny beads, called microspheres, class into up to 500 distinct sets. Each bead set can be coated with a reagent specific to a particular bioassay, allowing the capture and detection of specific analytes from a sample. Inside the Luminex analyzer, a light source excites the internal dyes that identify each microsphere particle, and also any reporter dye captured during the assay. Many readings are made on each bead set, which further validates the results.

Instrument—TESMI F4000

The TESMI F4000 System is a flexible analyzer based on the principles of flow cytometry. The system enables you to multiplex (simultaneously measure) up to 100 analytes in a single microplate well, using very small sample volumes. The system delivers fast and cost-effective bioassay results on many assay formats including nucleic acid assays, receptor-ligand assays, immunoassays and enzymatic assays.



Tumor Markers

Base on suspension bead array method, Tellgen developed Tellgenplex™ Tumor Marker Test which is intended for the simultaneous quantitative determination up to 13 tumor markers in 1 reaction. All these tumor markers were obtained clearance from SFDA. The customers could select these markers by singleplex or multiplex manner according to their needs. The kit could apply in both clinical test and personnel physical test, and became a cutting-end product in oncology biomarker screening area.

Singleplex markers

- F-PSA, T-PSA
- AFP, CEA, free- β -hCG
- NSE, CYFRA21-1, SCCA
- CA125, CA19-9, CA24-2, CA72-4, CA153, CA50

Panels recommended

- total-PSA、free-PSA (CE Marked)
- AFP、CEA
- NSE, CYFRA21-1. CEA
- CA242、CA125、CA19-9、CA15-3、CA50
NSE、CYFRA21-1、free- β -hCG、SCCA

Benifits

- Trace sample, multiple markers in 1 reaction
- Less sample-to-answer time, ~1 hours/96 samples
- Multiple combination according to your needs
- Most robust platform

Panels available

| NO. | Tumor Markers | CODE | Cat NO. | Tests |
|-----|---|-----------|----------|-------|
| 1 | CA125 | LP111010B | LP111010 | 96 |
| 2 | CA153 | LP011020A | LP011020 | 96 |
| 3 | CYFRA21-1 | LP111040A | LP111040 | 96 |
| 4 | AFP | LP111050B | LP111050 | 96 |
| 5 | CEA | LP111062A | LP111062 | 480 |
| 6 | CEA | LP111060A | LP111060 | 96 |
| 7 | total PSA | LP111080C | LP111080 | 96 |
| 8 | free PSA | LP111090A | LP111090 | 96 |
| 9 | free- β -hCG | LP111100B | LP111100 | 96 |
| 10 | CA19-9 | LP111110C | LP111110 | 96 |
| 11 | NSE | LP111070A | LP111070 | 96 |
| 12 | SCCA | LP011160 | LP011160 | 96 |
| 13 | CA50 | LP011180B | LP011180 | 96 |
| 14 | F-PSA/T-PSA | LP110050C | LP110050 | 96 |
| 15 | AFP/CEA | LP110060D | LP110060 | 96 |
| 16 | AFP/CEA/CA125/CA19-9 | LP110200A | LP110200 | 96 |
| 17 | AFP/CEA/CA125/CA19-9/T-PSA | LP110230B | LP110230 | 96 |
| 18 | AFP/CEA/CA125/CA19-9/T-PSA | LP110232C | LP110232 | 480 |
| 19 | AFP/CA125/CYFRA21-1/CA19-9 /CEA /free- β -hCG/NSE/F-PSA/T-PSA | LP110240A | LP110240 | 96 |
| 20 | AFP/CEA/CA125/CYFRA21-1/free- β -hCG/NSE/F-PSA/T-PSA | LP010300 | LP010300 | 96 |
| 21 | CA125/CA19-9 | LP110330C | LP110330 | 96 |
| 22 | CA19-9/total PSA | LP110360B | LP110360 | 96 |
| 23 | CA125/CA19-9/NSE/T-PSA | LP110370A | LP110370 | 96 |
| 24 | AFP/CEA/CA125/CA19-9/CYFRA21-1 | LP110380B | LP110380 | 96 |
| 25 | AFP/total PSA | LP110390A | LP110390 | 96 |
| 26 | AFP/CEA/total PSA | LP110440A | LP110440 | 96 |
| 27 | AFP/CEA/CA125 | LP110450A | LP110450 | 96 |
| 28 | CEA/CYFRA21-1/NSE | LP110460A | LP110460 | 96 |
| 29 | CYFRA21-1/NSE | LP110490A | LP110490 | 96 |
| 30 | CA19-9/F-PSA/T-PSA | LP110500A | LP110500 | 96 |
| 31 | AFP/CEA/F-PSA/T-PSA | LP110510A | LP110510 | 96 |

For other combination, please contact with us via email: zhaozhengzhen@tellgen.com

TECHNOLOGY--

Chemiluminescence immunoassay

Immunoassay: TESMI i100 and SMART 6500

TESMI i100



SMART 6500



| Type | TESMI i100 | SMART 6500 |
|-----------------------------|---------------------------|---------------------------|
| Maximum Throughput | 100 tests/hour | 360 tests/hour |
| Methods | acridinium | acridinium |
| Reagent Capacity | 15 refrigerated positions | 24 refrigerated positions |
| Sample Capacity | 24 | 96 |
| Cuvette | ≥130 | ≥1000 |
| Dimensions(H x W x D) | 648 x 500 x 645 mm | 700 x 1286 x 720 mm |
| Weight | 89 kg | 150 kg |
| Onboard Maintenance Records | Yes | Yes |

- ✓Tumor markers
 - ✓SARS-CoV-2 (IgG&IGM)
 - ✓Cardiac markers
 - ✓Thyroid funtion
 - ✓ToRCH
- ✓Autoimmune markers
 - ✓Fertility/ hormones
 - ✓Vitamin D
 - ✓Hepatitis /infectious disease
 - ✓Bone makers

Panels available

Tumor markers (20)

| | |
|---|--------------------|
| α -fetoprotein | AFP |
| Carcinoembryonic antigen | CEA |
| Neuron Specific Enolase | NSE |
| Cytokeratin fragment 19 | CYFRA21-1 |
| Carbohydrate antigen 125 | CA125 |
| Carbohydrate antigen 19-9 | CA19-9 |
| Squamous cell carcinoma antigen | SCCA |
| Total prostate specific antigen | tPSA |
| Free prostate specific antigen | fPSA |
| Free human chorionic gonadotropin hormone β subunit | free- β -hCG |
| pepsinogenI | PGI |
| pepsinogen II | PGII |
| ferritin | ferritin |
| β 2-microglobulin | β 2-MG |
| Carbohydrate antigen 15-3 | CA15-3 |
| pro-gastrin-releasing peptide | proGRP |
| Human epididymis protein 4 | HE4 |
| Carbohydrate antigen 72-4 | CA72-4 |
| Carbohydrate antigen 24-2 | CA24-2 |
| Carbohydrate antigen 50 | CA50 |

Thyroid function indicators (5)


| | |
|------------------------------|-----|
| Thyroid stimulating hormone, | TSH |
| Total serum thyroxine | TT3 |
| Free triiodothyronine | FT3 |
| The hormone thyroxine T4 | TT4 |
| Free Thyroxine, FT4 | FT4 |

For other combination, please contact with us via email: zhaozhengzhen@tellgen.com

Panels available

Myocardial and Inflammatory Markers

| | |
|--|-----------|
| Brain natriuretic peptide | BNP |
| N-terminal brain natriuretic peptide precursor | NT-ProBNP |
| high-sensitivity cardiac troponin I | hs-cTnI |
| CK-MB the MB isoenzyme of creatine kinase | CK-MB |
| Myoglobin | MYO |
| heart-type fatty acid-binding protein | H-FABP |
| Interleukin 6 | IL-6 |
| Procalcitonin | PCT |



For other combination, please contact with us via email: zhaozhengzhen@tellgen.com

TECHNOLOGY— Clinical Chemistry

General Clinical chemistry analyzers



- ✓ General chemistry
- ✓ Diabetes
- ✓ Anemia
- ✓ Cardiology and lipids
- ✓ specific protein
- ✓ coagulation
- ✓ Broad menu >60 items

TECHNOLOGY—

Molecular tests



- ✓ Sars-CoV-2
- ✓ HPV-27
- ✓ HPV2+12
- ✓ Lung-Me methylation for lung cancer
- ✓ Septin9 colorectal cancer blood screening
- ✓ Y6 chromosome microdeletion
- ✓ EGFR/K-RAS/B-RAF

SARS-CoV-2 Nucleic acid detection kit based on Real-Time PCR platform

The kit for the in vitro qualitative determination of N gene and S gene for SARS-CoV-2 in human throat swab and sputum. This kit is used for nucleic acid detection of SARS-CoV-2, and the results can be used for auxiliary diagnosis of patients with SARS-CoV-2 infection or patients suspected of COVID 19, and provide molecular diagnostic basis for infected patients. The test results of this kit are for clinical



Benifits

- High Specificity: A dual-target assay for the conserved region of spike protein S gene (FAM)
- Stable : Lyophilized form of the reagent can be transport at room temperature
- Multiple Applicable instrument: Any real-time PCR instrument with FAM / ROX / Cy5 detection channel

| | | | |
|---|------------------|-----------|------|
| 1 | Liquid form | PGA4102P1 | 48 |
| 2 | Lyophilized form | PGA4102P2 | 1414 |

SARS-CoV-2 Nucleic acid detection kit Based on Cartridge Real-Time PCR platform

The kit for the in vitro qualitative determination of two different target fragments of N gene for SARS-CoV-2 in human throat swab and sputum. This kit is used for nucleic acid detection of SARS-CoV-2, and the results can be used for auxiliary diagnosis of patients with SARS-CoV-2 infection or patients suspected of COVID 19, and provide molecular diagnostic basis for infected patients.



Benifits

- Applicable for rapid diagnosis of SARS-CoV-2
- Simple : No hands-on process for nucleic acid purification , no restrictions of licensed PCR labortory or qualified PCR technicians
- Safe : The whole process is performed in a closed system.

| | | | |
|---|-----------------------------------|-----------|----|
| 1 | Detection kit Cartridge PCR (N&N) | PGA4101P3 | 24 |
| 2 | Detection kit Cartridge PCR (O&N) | PGA4103P3 | 24 |
| 3 | Tellgen Life Ready 1000 (AIGS) | PJA0001 | |

Swab Transport Medium(Modified Hank's buffer)

The formulation of STM-HB contains Hanks's solution, which is suitable for subsequent molecular experiment (e.g. PCR amplification) after nucleic acid purification as well as virus isolation and cultivation. Contains a variety of antibiotics to inhibit the growth of bacteria and fungi . Suitable for collection and transportation of a variety of specimens including viruses, mycoplasma and chlamydia



| Package specification | Description | Pack |
|-----------------------|--|-----------------|
| PFA4X051 | Vial with 1.0ml transport medium, regular polyester tipped swab | 48 bottles/kit |
| PFA4X052 | Vial with 2.0ml transport medium, regular polyester tipped swab | 48 bottles/kit |
| PFA4X053 | Vial with 3.0ml transport medium, regular polyester tipped swab | 48 bottles/kit |
| PFA4X054 | Vial with 0.75ml transport medium, regular polyester tipped swab | 100 bottles/kit |
| PFA4X055 | Vial with 1.0ml transport medium, regular polyester tipped swab | 100 bottles/kit |

Swab Transport Medium(Modified Lysis buffer)

Swab Transport Medium (Modified Lysis buffer) is intended for the collection and transport of clinical samples containing tissue or cellular which used for pathology analysis from the collection site to the testing laboratory.



| Package specification | Description | Pack |
|-----------------------|--|-----------------|
| PFA4X042 | Vial with 1.8ml transport medium, regular polyester tipped swab | 48 bottles/kit |
| PFA4X043 | Vial with 3.0ml transport medium, regular polyester tipped swab | 48 bottles/kit |
| PFA4X044 | Vial with 0.75ml transport medium, regular polyester tipped swab | 100 bottles/kit |
| PFA4X045 | Vial with 1.0ml transport medium, regular polyester tipped swab | 100 bottles/kit |

Lung Me™ methylation test



This kit is a real time PCR assay, used for the detection of methylated human SHOX2 and RASSF1A genes in human bronchoalveolar lavage fluid.

Significance of DNA methylation


1. Differential diagnosis of benign and malignant lung lesions: In cases where it's impossible to diagnose lung cancer through cytological examination with bronchial bronchoalveolar lavage fluid, conducting the methylation detection of SHOX2 and RASSF1A genes can further improve the detection rate and specificity of lung cancer
2. Early screening of lung cancer: Researches have shown that gene methylation can be detected on asymptomatic patients before the emergence of clinical symptoms, thus to assist in early lung cancer diagnosis.

| | | | |
|---|---|-----------|----|
| 1 | SHOX2 and RASSF1A DNA methylation PCR Kit | PG09104F4 | 20 |
|---|---|-----------|----|

Septin9 colorectal cancer blood screening

This kit is a qualitative assay for the real-time PCR detection of methylated Septin9 DNA in bisulfite converted DNA from human plasma samples. Presence of methylated Septin9 is associated with, and may aid in, the detection of colorectal cancer.

Comprehensive Sensitivity of Screening for Stage I~IV Colorectal Cancer



| | | | |
|---|---|-----------|-----|
| 1 | Human methylated Septin9 DNA detection kit based on Real-Time PCR platform (Liquid Form) | PGA9105S4 | 20 |
| 2 | Human methylated Septin9 DNA detection kit based on Real-Time PCR platform (Liquid Form) | PGA9105S5 | 50 |
| 3 | Human methylated Septin9 DNA detection kit based on Real-Time PCR platform (Liquid Form) | PGA9105S6 | 100 |
| 4 | Human methylated Septin9 DNA detection kit based on Real-Time PCR platform (Lyophilized form) | PGA9105D4 | 20 |
| 5 | Human methylated Septin9 DNA detection kit based on Real-Time PCR platform (Lyophilized form) | PGA9105D5 | 50 |
| 6 | Human methylated Septin9 DNA detection kit based on Real-Time PCR platform (Lyophilized form) | PGA9105D6 | 100 |

HPV Genotyping

Cervical Cancer turn into the second killers of female Cancer all of the world and HPV DNA test become a very effective method to prevent Cervical Cancer. Tellgenplex™ HPV DNA Test is the unique kit which could show digital results of 14 high-risk HPV subtypes or 26 HPV subtypes with most solid consideration. The kit possesses lots of advantages, including all-round typing in 1 reaction, high sensitive and flexibility, liquid phase and 15 minutes fast hybridization. It was praised as cutting-end HPV genotyping product and applied in cervical cancer screening, female physical, cervical carcinoma assistant diagnose and therapeutic evaluation.

Panel 1: 14 high-risk HPV types (CE Marked)

16、18、31、33、35、39、45、51、52、56、58、59、66、68

Panel 2: 27 HPV types (SFDA cleared)

High-risk type: 16、18、26、31、33、35、39、45、52、58、26、51、55、56、59、53、66、68、82、83

Low-risk type: 6、11、40、42、44、61、73

Benifits

- Trace sample, multiple markers in 1 reaction
- Only 15 minutes hybridization
- High sensitive and flexibility

| | | | |
|---|--------------------------------------|----------|--------|
| 1 | High-risk HPV DNA Test (14 Subtypes) | LG010021 | 48 |
| 2 | 27 HPV DNA Test (27 Subtypes) | LG010011 | 202020 |

EGFR mutation analysis

Nonsmall-cell lung cancer (NSCLC) patients with a mutation in the epidermal growth-factor receptor (*EGFR*) gene appear to be more likely to benefit from gefitinib (*Iressa*) than from conventional chemotherapy.

The Epidermal Growth Factor Receptor (EGFR) activates an important pathway that leads to cell proliferation, differentiation, migration/motility, adhesion, protection from apoptosis, enhanced survival and gene transcription. A large body of experimental and clinical work supports the view that EGFR is a relevant target for cancer therapy. The development of selective tyrosine kinase inhibitors has become an important area of drug discovery for the treatment of a variety of solid tumors such as breast, ovarian and colorectal cancers, NSCLC, and carcinoma of the head and neck.

EGFR mutations can be seen in about 10-15% of patients. Patients with EGFR mutations have been reported to respond to selective anti-EGFR tyrosine kinase inhibitors. The EGFR mutation test offered by Tellgen will be able to detect these mutations and identify all those patients that may respond to these targeted therapies.

Methodology

Multiplex real-time PCR

Specimen Requirements

Formalin-fixed, paraffin-embedded tissue

unstained slides

Fresh snap frozen biopsy

FNA materials.

Tests available

29 mutations in 8 tubes

■T790M

■L858R

■L861Q

■S768IG719S, G719A and G719C

■3 insert mutation in exon 20

■19 deletion mutation in exon 19

EGFR mutation analysis

Methodology

xMAP technology

Specimen Requirements

Formalin-fixed

paraffin-embedded tissue

unstained slides.

Fresh snap frozen biopsy

FNA materials.

Tests available

8 most common mutations in 1 tube

| Mutation | Exon | Base change |
|-----------------|------|----------------|
| G719C | 18 | 2155G>T |
| E746-A750del(1) | 19 | 2235_2249del15 |
| E746-A750del(2) | 19 | 2236_2250del15 |
| L747_T751>S | 19 | 2240_2251del12 |
| L747_P753>S | 19 | 2240_2257del18 |
| L858R | 21 | 2573T>G |
| L861Q | 21 | 2582T>A |
| T790M | 20 | 2369C>T |

KRAS mutation analysis

KRAS has been extensively studied in a wide array of human malignancies, including mCRC. Mutant KRAS can be detected in approximately 30-50% of colorectal cancers. The Ras-Raf-MAPK pathway lies just downstream of EGFR. The hypothesis suggests that a mutation in KRAS could render cells independent of upstream EGFR activation or inhibition of the receptor through anti-EGFR therapies. Several recent studies now show strong correlation of KRAS mutation with response to Erbitux® (cetuximab) and Vectibix™ (panitumumab). These studies show compelling evidence that KRAS mutations are a biomarker of non-responsiveness to either of these drugs in mCRC patients. In addition to being a predictive marker in mCRC, KRAS mutations are a sign of poor prognosis in many other clinical indications.

Methodology

Multiplex real-time PCR

Specimen Requirements

- Formalin-fixed
- paraffin-embedded tissue
- unstained slides.
- Fresh snap frozen biopsy
- FNA materials.

Benefits

- Hands on time: <30 min
- Sample to answer time: <90 min
- Sensitivity: ~1%

Tests available

| Mutation | Base Change |
|----------|-------------|
| Gly12Asp | GGT>GAT |
| Gly12Val | GGT>GTT |
| Gly12Ser | GGT>AGT |
| Gly12Cys | GGT>TGT |
| Gly12Ala | GGT>GCT |
| Gly12Arg | GGT>CGT |
| Gly13Asp | GGC>GAC |

KRAS-BRAF mutation analysis

Methodology

xMAP technology

Benefits

>95% mutation in 1 well

Sample to answer time: <3 hr

Sensitivity: ~1%

Specimen Requirements

Formalin-fixed

paraffin-embedded tissue

unstained slides

Fresh snap frozen biopsy

FNA materials.

Tests available

| Gene | Mutation | Base Change |
|------|----------|-------------|
| KRAS | Gly12Asp | GGT>GAT |
| | Gly12Val | GGT>GTT |
| | Gly12Ser | GGT>AGT |
| | Gly12Cys | GGT>TGT |
| | Gly12Ala | GGT>GCT |
| | Gly12Arg | GGT>CGT |
| | Gly13Asp | GGC>GAC |
| | Gly13Cys | GGC>TGC |
| BRAF | V600E | T>A |

BRAF V600E mutation analysis

The BRAF (V600E) mutation analysis is predictive for anti-EGFR therapies (i.e., cetuximab and panitumumab). BRAF mutations account for approximately 12-15% of colorectal cancer patients

Methodology

real-time PCR

Specimen Requirements

Formalin-fixed

paraffin-embedded tissue

unstained slides

Fresh snap frozen biopsy

FNA materials.

Y-chromosome Micro-deletions

Micro-deletions of the Y chromosome are the second most frequent genetic cause of male infertility after the Klinefelter syndrome. The portion of the male-specific region of the Y chromosome (MSY), comprising 95% of the Y chromosome and flanked by pseudoautosomal regions, which is affected by deletions has been classically subdivided into three regions called AZFa, AZFb and AZFc, respectively. Deletions of the three AZF areas will lead to spermatogenetic failure resulting in male infertility. According to EAA/EMQN best practice guideline for molecular diagnosis of Y-chromosome micro-deletions, Tellgen developed **Y chromosome Micro-deletions Diagnostic Kit** to detect 6 STS micro-deletions based on multiplex PCR. Set A primer includes sY254, sY127 and sY86, set B primer includes sY134, sY84 and sY255. SRY gene acts as PCR internal control for the testis-determining factor on the short arm of the Y chromosome and for the presence of Y-specific sequences when the ZFY gene is absent.

Methodology

multiplex PCR

Specimen Requirements

Peripheral blood

Benefits

Hands-on time: <30 min

Sample to answer time: <2 hr

High specificity and low cost



| Products | loci | Cat. No. | Tests |
|---|-----------------------------------|----------|-------|
| Tellgenplex™ Y-chromosome microdeletion kit | sY84、sY86、sY127、sY134、sY254、sY255 | PG020012 | 20 |

Service & Support

Research Service

We provide comprehensive research service in

Probe label

Antibody label

Antibody-bead conjugation

Probe-bead conjugation

After-sale Support

Further support is provided in the form of continued technology transfer through regular updates on equipment and processing methods, and the company is always available to provide assistance, guidance and advice.

- Applications and Technical support
- strong customer focus
- development for usability &serviceability
- minimal after-sale costs.

Contact Information

Products Counseling & Order Management

Phone: +86-21-5027 3497

Fax: +86-21-5080 0020

E-mail: zhaozhengzhen@tellgen.com

Technical Support

Fax: +86-21-5080 0020

E-mail: support@tellgen.com



Shanghai Tellgen Life Science Co., Ltd.

Add: NO.646, Zhangjiang Hi-Tech Park, Pudong, Shanghai P.R.China

Code: 201203

Tel: +86-21-38685570

Fax: +86-21-50800020

E-mail: zhaozhengzhen@tellgen.com